Literature DB >> 9058294

Alterations in the tumor suppressor genes p53, RB, p16/MTS1, and p15/MTS2 in human pancreatic cancer and hepatoma cell lines.

M Kaino1.   

Abstract

The tumor suppressor genes p53, retinoblastoma (RB), p16, and p15 encode proteins that regulate the cell cycle cooperatively by controlling the transition from G1 to S phase and may play an important role in cell growth and differentiation. To screen for abnormalities in these genes in cancer, we performed genetic analysis in six human pancreatic cancer and five hepatoma cell lines, by single-strand conformation polymorphism (SSCP) analysis, direct sequencing, and the reverse transcriptase-polymerase chain reaction (RT-PCR). All six pancreatic cancer cell lines had p53 mutations, with the concomitant loss of the other normal allele, encoding wild-type p53. Frequent homozygous deletions were found in p16 and p15, but the RB gene was expressed. Four of the five hepatoma cell lines had p53 mutations with loss of the normal allele and aberrant RB. There were no deletions of p16 and p15 in any of the hepatoma cell lines. These findings suggest that alterations in the p53, p16, and p15 genes are common in human pancreatic cancer cell lines, while p53 or RB mutations are common in hepatoma cell lines. Alterations of these tumor suppressor genes may thus be important features in organ-specific carcinogenesis.

Entities:  

Mesh:

Year:  1997        PMID: 9058294     DOI: 10.1007/bf01213295

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  25 in total

Review 1.  Molecular themes in oncogenesis.

Authors:  J M Bishop
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

2.  Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines.

Authors:  A Puisieux; K Galvin; F Troalen; B Bressac; C Marcais; E Galun; F Ponchel; C Yakicier; J Ji; M Ozturk
Journal:  FASEB J       Date:  1993-11       Impact factor: 5.191

Review 3.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

4.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

5.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.

Authors:  T Nobori; K Miura; D J Wu; A Lois; K Takabayashi; D A Carson
Journal:  Nature       Date:  1994-04-21       Impact factor: 49.962

Review 6.  Multiple steps in carcinogenesis involving alterations of multiple tumor suppressor genes.

Authors:  J Yokota; T Sugimura
Journal:  FASEB J       Date:  1993-07       Impact factor: 5.191

Review 7.  K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.

Authors:  R H Hruban; A D van Mansfeld; G J Offerhaus; D H van Weering; D C Allison; S N Goodman; T W Kensler; K K Bose; J L Cameron; J L Bos
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

8.  Accumulation of allelic loss on arms of chromosomes 13q, 16q and 17p in the advanced stages of human hepatocellular carcinoma.

Authors:  N Nishida; Y Fukuda; H Kokuryu; T Sadamoto; G Isowa; K Honda; Y Yamaoka; M Ikenaga; H Imura; K Ishizaki
Journal:  Int J Cancer       Date:  1992-07-30       Impact factor: 7.396

9.  Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer.

Authors:  G Berrozpe; J Schaeffer; M A Peinado; F X Real; M Perucho
Journal:  Int J Cancer       Date:  1994-07-15       Impact factor: 7.396

10.  K-ras and p53 alterations in genomic DNA and transcripts of human pancreatic adenocarcinoma cell lines.

Authors:  H Suwa; T Yoshimura; N Yamaguchi; K Kanehira; T Manabe; M Imamura; H Hiai; M Fukumoto
Journal:  Jpn J Cancer Res       Date:  1994-10
View more
  9 in total

1.  Fluorine-18 Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma: Correlation with Glucose Transporters and p53 Expression.

Authors:  Ana F Brito; Ana M Abrantes; Marina Ribeiro; Rui Oliveira; João Casalta-Lopes; Ana C Gonçalves; Ana B Sarmento-Ribeiro; José G Tralhão; Maria F Botelho
Journal:  J Clin Exp Hepatol       Date:  2015-06-03

2.  Werner syndrome as a hereditary risk factor for exocrine pancreatic cancer: potential role of WRN in pancreatic tumorigenesis and patient-tailored therapy.

Authors:  Stephen G Chun; Nelson S Yee
Journal:  Cancer Biol Ther       Date:  2010-09-22       Impact factor: 4.742

3.  Tumor suppression by MEG3 lncRNA in a human pituitary tumor derived cell line.

Authors:  Paweena Chunharojrith; Yuki Nakayama; Xiaobing Jiang; Rachel E Kery; Jun Ma; Cristine S De La Hoz Ulloa; Xun Zhang; Yunli Zhou; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2015-08-15       Impact factor: 4.102

4.  Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers.

Authors:  Maggie J Rathos; Kavita Joshi; Harshal Khanwalkar; Sonal M Manohar; Kalpana S Joshi
Journal:  J Transl Med       Date:  2012-08-08       Impact factor: 5.531

5.  Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model.

Authors:  Zhi Yang; Qianzhen Zhang; Ke Xu; Juanjuan Shan; Junjie Shen; Limei Liu; Yanmin Xu; Feng Xia; Ping Bie; Xia Zhang; Youhong Cui; Xiu-Wu Bian; Cheng Qian
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

6.  Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint.

Authors:  Matthew T Huggett; Slavica Tudzarova; Ian Proctor; Marco Loddo; Margaret G Keane; Kai Stoeber; Gareth H Williams; Stephen P Pereira
Journal:  Oncotarget       Date:  2016-04-05

7.  p53 mutations in two patients with intraductal papillary adenoma of the pancreas.

Authors:  M Kaino; S Kondoh; S Okita; S Ryozawa; S Hatano; K Shiraishi; S Kaino; T Akiyama; K Okita; T Kawano
Journal:  Jpn J Cancer Res       Date:  1996-12

8.  Influence of P53 on the radiotherapy response of hepatocellular carcinoma.

Authors:  Ana R Gomes; Ana M Abrantes; Ana F Brito; Mafalda Laranjo; João E Casalta-Lopes; Ana C Gonçalves; Ana B Sarmento-Ribeiro; Maria F Botelho; José G Tralhão
Journal:  Clin Mol Hepatol       Date:  2015-09-30

9.  Depletion of runt-related transcription factor 2 (RUNX2) enhances SAHA sensitivity of p53-mutated pancreatic cancer cells through the regulation of mutant p53 and TAp63.

Authors:  Takehiro Ogata; Mizuyo Nakamura; Meijie Sang; Hiroyuki Yoda; Kiriko Hiraoka; Danjing Yin; Mexiang Sang; Osamu Shimozato; Toshinori Ozaki
Journal:  PLoS One       Date:  2017-07-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.